Finerenone in Cardio-Kidney-Metabolic Syndrome With Cancer History: FINE-HEART Insights

Ruppert and colleagues analysed participant-level data from the FINE-HEART pooled programme, combining FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF. Of 18,991 participants, 1,389 (7.3%) had a previous cancer diagnosis. A cancer history was associated with more advanced cardio-kidney-metabolic burden and higher risks of death and hospitalisation.

Across cancer-history subgroups, finerenone’s effects on the analysed clinical outcomes were reported as consistent. The pooled analysis found no evidence that a previous cancer diagnosis diminished the observed benefits on all-cause death, heart failure, hospitalisation, kidney outcomes, major adverse cardiovascular events, or new-onset atrial fibrillation.

The findings are reassuring within the trial populations, but they should not be read as cancer-treatment evidence or as a universal recommendation. This was a post hoc pooled analysis; cancer type, active malignancy, comedications, kidney function, potassium risk, and local prescribing guidance remain important in individual decisions.

Editorial note: Bayer AG is listed in the PubMed funding record. This professional summary is not patient-specific prescribing advice.